Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Supplements And Featured Publications, Diagnosis and Trial Options in Sarcoma, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>Yale Cancer Center</b>

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate cancer center director, Experimental Therapeutics, Yale School of Medicine, discusses the importance of clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

For patients who present with MDM2-amplified dedifferentiated liposarcoma, enrolling them in a clinical trial for an MDM2 inhibitor, such as BI 907828, at a site that has a clinical trial opened, would be an ideal treatment approach, LoRusso explains. BI 907828 is an important drug for this particular tumor type with an MDM2 alteration, LoRusso adds. Moreover, BI 907828 demonstrated efficacy in a prior phase 1 trial (NCT03449381), and the soft tissue sarcoma community should be alerted to this drug, LoRusso says. 

BI 907828 is now under further investigation in the phase 2/3 Brightline-1 trial (NCT05218499) in patients with dedifferentiated liposarcoma. Patients with this MDM2 amplifications could benefit from enrollment, LoRusso concludes.